Federico Mocchegiani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6622549/publications.pdf

Version: 2024-02-01

89 papers

3,098 citations

145106 33 h-index 52 g-index

89 all docs 89 docs citations

89 times ranked

3761 citing authors

#	Article	IF	CITATIONS
1	Outcome of major hepatectomy in cirrhotic patients; does surgical approach matter? A propensity score matched analysis. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 1226-1239.	1.4	9
2	Re-thinking of T-tube use in whole liver transplantation: an analysis on the risk of delayed graft function. Updates in Surgery, 2022, 74, 571-577.	0.9	2
3	Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation. Frontiers in Oncology, 2022, 12, 877107.	1.3	5
4	The role of the comprehensive complication index for the prediction of survival after liver transplantation. Updates in Surgery, 2021, 73, 209-221.	0.9	7
5	Postoperative Trends and Prognostic Values of Inflammatory and Nutritional Biomarkers after Liver Transplantation for Hepatocellular Carcinoma. Cancers, 2021, 13, 513.	1.7	16
6	Assessment of Textbook Outcome in Laparoscopic and Open Liver Surgery. JAMA Surgery, 2021, 156, e212064.	2.2	73
7	Minimally Invasive Stage 1 to Protect Against the Risk of Liver Failure: Results from the Hepatocellular Carcinoma Series of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Italian Registry. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 1082-1089.	0.5	13
8	Mild impact of SARS-CoV-2 infection on the entire population of liver transplant recipients: the experience of an Italian Centre based in a high-risk area. Updates in Surgery, 2020, 72, 1291-1293.	0.9	4
9	Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study. Oncology and Therapy, 2020, 8, 115-124.	1.0	4
10	Controlling Nutritional Status score does not predict patients' overall survival or hepatocellular carcinoma recurrence after deceased donor liver transplantation. Clinical Transplantation, 2020, 34, e13786.	0.8	7
11	Surgical Complications Requiring an Early Relaparotomy in HIV-Infected Liver Transplant Recipients: Risk Factors and Impact on Survival. Transplantation Proceedings, 2019, 51, 2977-2980.	0.3	2
12	CYP2B6, ABCB1 and OPRM1 profile in a stillborn affected by chronic methadone intoxication. Forensic Toxicology, 2019, 37, 507-516.	1.4	3
13	Early postâ€liver transplant surgical morbidity in <scp>HIV</scp> â€infected recipients: risk factor for overall survival? A nationwide retrospective study. Transplant International, 2019, 32, 1044-1052.	0.8	2
14	Surgery for cholangiocarcinoma. Liver International, 2019, 39, 143-155.	1.9	192
15	Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case. American Journal of Transplantation, 2019, 19, 2939-2943.	2.6	7
16	Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature. World Journal of Gastrointestinal Surgery, 2019, 11, 279-286.	0.8	21
17	Impact of aberrant left hepatic artery ligation on the outcome of liver transplantation. Liver Transplantation, 2018, 24, 204-213.	1.3	14
18	Impact of Graft Steatosis on Postoperative Complications after Liver Transplantation. The Surgery Journal, 2018, 04, e188-e196.	0.3	8

#	Article	IF	CITATIONS
19	Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World Journal of Gastroenterology, 2017, 23, 3690.	1.4	29
20	Predictive factors of short term outcome after liver transplantation: A review. World Journal of Gastroenterology, 2016, 22, 5936.	1.4	66
21	Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients. BMC Infectious Diseases, 2016, 16, 538.	1.3	24
22	Fast track program in liver resection. Medicine (United States), 2016, 95, e4154.	0.4	24
23	Prevalence and clinical outcome of hepatic haemangioma with specific reference to the risk of rupture: A large retrospective cross-sectional study. Digestive and Liver Disease, 2016, 48, 309-314.	0.4	61
24	Effects of the Infusion of 4% or 20% Human Serum Albumin on the Skeletal Muscle Microcirculation in Endotoxemic Rats. PLoS ONE, 2016, 11, e0151005.	1.1	17
25	Immunological Risk Factors in Biliary Strictures after Liver Transplantation. Annals of Transplantation, 2015, 20, 218-224.	0.5	18
26	Postoperative Insulin-Like Growth Factor 1 Levels Reflect the Graft's Function and Predict Survival after Liver Transplantation. PLoS ONE, 2015, 10, e0133153.	1.1	8
27	ALPPS Procedure for Extended Liver Resections: A Single Centre Experience and a Systematic Review. PLoS ONE, 2015, 10, e0144019.	1.1	42
28	Transoesophageal echocardiography during liver transplantation. World Journal of Hepatology, 2015, 7, 2432.	0.8	30
29	Metastatic breast cancer mimicking a hilar cholangiocarcinoma: case report and review of the literature. World Journal of Surgical Oncology, 2014, 12, 384.	0.8	16
30	Liver Transplantation in Neurological Wilson's Disease: Is There Indication? A Case Report. Transplantation Proceedings, 2014, 46, 2360-2364.	0.3	12
31	Liver Transplantation in Patients with Common Variable Immunodeficiency: A Report of Two Cases. Annals of Transplantation, 2014, 19, 541-544.	0.5	18
32	Tacrolimus and Everolimus De Novo versus Minimization of Standard Dosage of Tacrolimus Provides a Similar Renal Function at One Year after Liver Transplantation: A Case-Control Matched-Pairs Analysis. Annals of Transplantation, 2014, 19, 545-550.	0.5	6
33	Quorum sensing inhibitor FS3-coated vascular graft enhances daptomycin efficacy in a rat model of staphylococcal infection. Peptides, 2013, 40, 77-81.	1.2	45
34	Semaphorin 7A Contributes to TGF-β–Mediated Liver Fibrogenesis. American Journal of Pathology, 2013, 183, 820-830.	1.9	46
35	Resected biliary tract cancers: A novel clinical–pathological score correlates with global outcome. Digestive and Liver Disease, 2013, 45, 70-74.	0.4	10
36	The Efficacy of the Quorum Sensing Inhibitor FS8 and Tigecycline in Preventing Prosthesis Biofilm in an Animal Model of Staphylococcal Infection. International Journal of Molecular Sciences, 2013, 14, 16321-16332.	1.8	37

#	Article	IF	CITATIONS
37	Doxorubicin-eluting bead i>vsconventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World Journal of Gastroenterology, 2013, 19, 5622.	1.4	52
38	Efficacy of Tigecycline and Rifampin Alone and in Combination against Enterococcus faecalis Biofilm Infection in a Rat Model of Ureteral Stent. Journal of Surgical Research, 2012, 176, 1-6.	0.8	36
39	Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis. Critical Care Medicine, 2009, 37, 1403-1407.	0.4	30
40	Comparative Efficacy of Topical Versus Systemic Teicoplanin in Experimental Model of Wound Infections. Journal of Surgical Research, 2008, 144, 74-81.	0.8	10
41	Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of tazobactam/piperacillin in a neutropenic mouse model of polymicrobial peritonitis. Peptides, 2008, 29, 31-38.	1.2	4
42	BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection. Peptides, 2008, 29, 1118-1123.	1.2	28
43	Protective effects of the combination of α-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. Journal of Antimicrobial Chemotherapy, 2008, 62, 1332-1338.	1.3	59
44	Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis. Critical Care Medicine, 2008, 36, 240-245.	0.4	11
45	Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococcal sepsis. Critical Care Medicine, 2008, 36, 2629-2633.	0.4	14
46	Efficacy of Tachyplesin III, Colistin, and Imipenem against a Multiresistant Pseudomonas aeruginosa Strain. Antimicrobial Agents and Chemotherapy, 2007, 51, 2005-2010.	1.4	47
47	RNAIII-Inhibiting Peptide Affects Biofilm Formation in a Rat Model of Staphylococcal Ureteral Stent Infection. Antimicrobial Agents and Chemotherapy, 2007, 51, 4518-4520.	1.4	57
48	Pretreatment With the Protegrin IBâ€367 Affects Gramâ€Positive Biofilm and Enhances the Therapeutic Efficacy of Linezolid in Animal Models of Central Venous Catheter Infection. Journal of Parenteral and Enteral Nutrition, 2007, 31, 463-468.	1.3	27
49	Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain*. Critical Care Medicine, 2007, 35, 1717-1723.	0.4	34
50	The lipopeptides Pal–Lys–Lys–NH2 and Pal–Lys–Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection. Peptides, 2007, 28, 1299-1303.	1.2	22
51	Treatment of Staphylococcus aureus Biofilm Infection by the Quorum-Sensing Inhibitor RIP. Antimicrobial Agents and Chemotherapy, 2007, 51, 2226-2229.	1.4	170
52	Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. Journal of Biomedical Materials Research - Part A, 2007, 81A, 233-239.	2.1	11
53	Estrogens maintain bile duct mass and reduce apoptosis after biliodigestive anastomosis in bile duct ligated rats. Journal of Hepatology, 2006, 44, 1158-1166.	1.8	16
54	Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides, 2006, 27, 1210-1216.	1.2	46

#	Article	IF	CITATIONS
55	Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides, 2006, 27, 2104-2110.	1.2	49
56	Experimental study on the efficacy of combination of α-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. Peptides, 2006, 27, 2600-2606.	1.2	24
57	Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide. Peptides, 2006, 27, 2592-2599.	1.2	8
58	Amphibian peptides prevent endotoxemia and bacterial translocation in bile duct–ligated rats*. Critical Care Medicine, 2006, 34, 2415-2420.	0.4	27
59	RNAIII-INHIBITING PEPTIDE IN COMBINATION WITH THE CATHELICIDIN BMAP-28 REDUCES LETHALITY IN MOUSE MODELS OF STAPHYLOCOCCAL SEPSIS. Shock, 2006, 26, 296-301.	1.0	10
60	THE CATHELICIDIN-DERIVED TRITRPTICIN ENHANCES THE EFFICACY OF ERTAPENEM IN EXPERIMENTAL RAT MODELS OF SEPTIC SHOCK. Shock, 2006, 26, 195-200.	1.0	12
61	RNAIIIâ€Inhibiting Peptide Significantly Reduces Bacterial Load and Enhances the Effect of Antibiotics in the Treatment of Central Venous Catheter–AssociatedStaphylococcus aureusInfections. Journal of Infectious Diseases, 2006, 193, 180-186.	1.9	88
62	LL-37 Protects Rats against Lethal Sepsis Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2006, 50, 1672-1679.	1.4	136
63	Interaction of Antimicrobial Peptide Temporin L with Lipopolysaccharide In Vitro and in Experimental Rat Models of Septic Shock Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2006, 50, 2478-2486.	1.4	65
64	Temporin A Alone and in Combination with Imipenem Reduces Lethality in a Mouse Model of Staphylococcal Sepsis. Journal of Infectious Diseases, 2005, 192, 1613-1620.	1.9	15
65	Comparative Efficacies of Quinupristin-Dalfopristin, Linezolid, Vancomycin, and Ciprofloxacin in Treatment, Using the Antibiotic-Lock Technique, of Experimental Catheter-Related Infection Due to Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2005, 49, 4042-4045.	1.4	50
66	Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides, 2005, 26, 207-216.	1.2	21
67	RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides, 2005, 26, 169-175.	1.2	42
68	Cathelicidin Peptide Sheep Myeloid Antimicrobial Peptide-29 Prevents Endotoxin-induced Mortality in Rat Models of Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 187-194.	2.5	72
69	A Chimeric Peptide Composed of a Dermaseptin Derivative and an RNA III-Inhibiting Peptide Prevents Graft-Associated Infections by Antibiotic-Resistant Staphylococci. Antimicrobial Agents and Chemotherapy, 2004, 48, 2544-2550.	1.4	60
70	Temporin A Soaking in Combination with Intraperitoneal Linezolid Prevents Vascular Graft Infection in a Subcutaneous Rat Pouch Model of Infection with Staphylococcus epidermidis with Intermediate Resistance to Glycopeptides. Antimicrobial Agents and Chemotherapy, 2004, 48, 3162-3164.	1.4	9
71	Potential Therapeutic Role of Histatin Derivative Pâ€113din Experimental Rat Models ofPseudomonas aeruginosaSepsis. Journal of Infectious Diseases, 2004, 190, 356-364.	1.9	38
72	Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models. Journal of Antimicrobial Chemotherapy, 2004, 54, 654-660.	1.3	37

#	Article	IF	Citations
73	Cecropin B Enhances Betalactams Activities in Experimental Rat Models of Gram-Negative Septic Shock. Annals of Surgery, 2004, 239, 251-256.	2.1	26
74	The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis*. Critical Care Medicine, 2004, 32, 2485-2490.	0.4	54
75	Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock. Peptides, 2003, 24, 1747-1752.	1.2	33
76	RNA III Inhibiting Peptide Inhibits In Vivo Biofilm Formation by Drug-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2003, 47, 1979-1983.	1.4	120
77	Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. Journal of Antimicrobial Chemotherapy, 2003, 52, 724-726.	1.3	11
78	Use of the Quorumâ€Sensing Inhibitor RNAIIIâ€Inhibiting Peptide to Prevent Biofilm Formation In Vivo by Drugâ€ResistantStaphylococcus epidermidis. Journal of Infectious Diseases, 2003, 187, 625-630.	1.9	162
79	Prophylactic Efficacy of Topical Temporin A and RNAIII-Inhibiting Peptide in a Subcutaneous Rat Pouch Model of Graft Infection Attributable to Staphylococci With Intermediate Resistance to Glycopeptides. Circulation, 2003, 108, 767-771.	1.6	78
80	Neutralization of Endotoxin In Vitro and In Vivo by BAC7(1-35), a Proline-Rich Antibacterial Peptide. Shock, 2003, 19, 577-581.	1.0	32
81	Efficacy of Quinupristin-Dalfopristin in Preventing Vascular Graft Infection Due to Staphylococcus epidermidis with Intermediate Resistance to Glycopeptides. Antimicrobial Agents and Chemotherapy, 2002, 46, 2885-2888.	1.4	10
82	Potential Therapeutic Role of Cationic Peptides in Three Experimental Models of Septic Shock. Antimicrobial Agents and Chemotherapy, 2002, 46, 2132-2136.	1.4	60
83	Cationic Peptides Combined with Betalactams Reduce Mortality from Peritonitis in Experimental Rat Model. Journal of Surgical Research, 2002, 108, 107-111.	0.8	12
84	Temporin A as a prophylactic agent against methicillin sodium-susceptible and methicillin sodium-resistant Staphylococcus epidermidis vascular graft infection. Journal of Vascular Surgery, 2002, 36, 1027-1030.	0.6	30
85	Single-Dose Intraperitoneal Magainins Improve Survival in a Gram-Negative-Pathogen Septic Shock Rat Model. Antimicrobial Agents and Chemotherapy, 2002, 46, 101-104.	1.4	37
86	Prophylaxis against Staphylococcus aureus Vascular Graft Infection with Mupirocin-Soaked, Collagen-Sealed Dacron. Journal of Surgical Research, 2001, 99, 316-320.	0.8	20
87	Therapeutic Efficacy of the Polymyxin-like Peptide Ranalexin in an Experimental Model of Endotoxemia. Journal of Surgical Research, 2001, 100, 183-188.	0.8	10
88	Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Critical Care Medicine, 2001, 29, 1666-1669.	0.4	36
89	Polycationic Peptides as Prophylactic Agents against Methicillin-Susceptible or Methicillin-Resistant Staphylococcus epidermidis Vascular Graft Infection. Antimicrobial Agents and Chemotherapy, 2000, 44, 3306-3309.	1.4	32